Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development-Reference-Cited by-同舟云学术

Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development

Published:2017-02-20 Issue:3 Volume:23 Page:350-352
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Iorio A.¹^ORCID

Affiliation:

1. Health Research Methods; Evidence and Impact; McMaster University; Hamilton ON Canada

Funder

Bayer

Baxalta

Biogen Idec

Grifols

Novo Nordisk

Pfizer

Octapharma

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13176/fullpdf

Reference22 articles.

1. Are randomized clinical trials the only truth? Not always;Aledort;J Thromb Haemost,2006

2. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia;Manco-Johnson;N Engl J Med,2007

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study);Gringeri;J Thromb Haemost,2011

4. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART);Manco-Johnson;J Thromb Haemost,2013

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for hemophilia A: insights into phase II and III clinical trials;Expert Opinion on Emerging Drugs;2021-10-02

2. Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015;Thrombosis Research;2021-02

3. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time;Transfusion and Apheresis Science;2019-10

4. Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments;HEMATOLOGIE;2019

5. Safety of recombinant coagulation factors in treating hemophilia;Expert Opinion on Drug Safety;2019-02-01